| Phone | 46-18-65-39-00 |
| Employees | |
| Founded | 1998 |
| TOTAL | $14M |
| VENTURE FUNDING TOTAL | $14M |
| Series C, 9/06 BankInvest Biomedical Venture Industrifonden HealthCap Innovations Kapital GSK Venture Fund | $14M |
Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.
